Skip to Content

Research

ONT 380 206

Research

Research

Clinicaltrial.gov identifier:
NCT02614794
Status:
Recruiting
Scenario:
Locally Advanced or Metastatic
Tumour subtype:
HER2+
Phase:
Phase II
Drug/Intervention:
ONT-380

Addition of the selective anti-HER2 agent ONT-380 to the treatment with capecitabine and trastuzumab in pretreated HER2+ breast cancer patients

Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Sponsors

OncoThyreon

X
Utilizamos cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Puede cambiar la configuración u obtener más información aquí.